Psoriatic Arthritis
Overweight and obesity are common comorbidities in psoriatic arthritis (PsA) and can negatively affect disease activity and treatment response. The phase 3b TOGETHER-PsA trial evaluated the concomitant use of ixekizumab and tirzepatide in adults with PsA and overweight or obesity. In this interview, conducted at EULAR 2026, Dr Laura Coates (University of Oxford, Oxford, UK) discusses the rationale for this combination approach, highlights the study’s key findings, and considers their potential implications for the future management of PsA.
The US Food and Drug Administration (FDA) has approved deucravacitinib as the first tyrosine kinase 2 (TYK2) inhibitor for adults with active psoriatic arthritis (PsA), marking a new targeted treatment option for this chronic inflammatory disease. In the phase 3 POETYK PsA-1 and PsA-2 trials, the once-daily oral therapy significantly improved disease activity compared with placebo, with over half of treated patients achieving an ACR20 response at Week 16. By selectively inhibiting TYK2 signalling pathways involved in psoriatic disease, deucravacitinib offers a novel mechanism distinct from traditional JAK inhibitors, expanding its role beyond plaque psoriasis and introducing a new oral option for patients with PsA.
The phase 3 POETYK PsA-1 trial evaluated deucravacitinib, an oral, selective TYK2 inhibitor in adults with psoriatic arthritis who were naĂŻve to biologic DMARDs. The 52-week findings were presented at the recent ACR Convergence 2025 meeting. In this interview, Prof. Philip Mease explored the mechanism of action, study design, and outcomes, emphasizing the role of TYK2 inhibition as a promising and well-tolerated oral therapeutic approach in psoriatic arthritis.
As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!
touchIMMUNOLOGY coverage of EULAR 2025: The 2025 European Alliance of Associations for Rheumatology (EULAR) Congress brought together leading rheumatologists, immunologists, and allied healthcare professionals from across Europe and beyond. Running from June 11–14 in Barcelona, the conference showcased the latest advances in immune-mediated ...
The Phase II ARGO trial evaluated the IL-17A and IL-17F inhibitor sonelokimab in psoriatic arthritis, showing promising clinical efficacy and significant improvements in patient-reported outcomes (PROs). In this interview, Prof. Laure Gossec highlights how sonelokimab reduced disease burden and improved quality of life, emphasizing the importance of PROs in assessing treatment effectiveness and guiding future development.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.
To gain expert insight into the most impactful developments of the past year and the trends set to shape the next, we reached out to our esteemed expert faculty. From advances in targeted therapies to the integration of AI and steps towards precision medicine, here’s what our experts had to say.
On September 23, 2024, the U.S. Food and Drug Administration (FDA) approved bimekizumab-bkzx (BIMZELX®, UCB) for the treatment of active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).1 This makes bimekizumab-bkzx ...
As we have come to expect, EULAR 2024 was a busy and productive meeting, packed with news and lively discussions among rheumatologists. The conference, which took place in Vienna, Austria, highlighted a wealth of innovative research and significant advancements in rheumatology. ...
To understand what sets izokibep apart from other IL-17 inhibitors and its potential for treating PsA, we spoke with one of the study's investigators, Prof. Peter Taylor. Prof. Taylor discusses the study's findings, focusing on its efficacy and tolerability, and explores what these results could mean for clinical practice. With several IL-17 inhibitors already approved or in development for PsA, we also examine how izokibep could fit into the current treatment paradigm. Additionally, we discuss the importance of ongoing research to fully determine izokibep's benefit/risk ratio and optimal dosage
Psoriatic arthritis (PsA) is a typical complication of psoriasis (PSO) that is often accompanied by nail PSO, vertebral and/or pelvic involvement, enthesitis and iritis. PsA leads to the destruction and/or ankylosis of the peripheral joints or spine, resulting ...
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial ...
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
